On the 3rd, CNR Research announced that it will strengthen its domestic and global customized consulting capabilities by hiring Dr. Jiwon Jeong, a statistics expert from the Ministry of Food and Drug Safety.
Dr. Jeong Ji-won will be in charge of customized consulting services on new drug development plans and strategy establishment as a BS (Biostatistics) advisor under the Data Solution Headquarters of CNR Research. Based on his experience as a clinical statistician at a leading domestic pharmaceutical company and his extensive experience at the Ministry of Food and Drug Safety, Dr. Jeong has a deep understanding of the requirements of the Ministry of Food and Drug Safety for domestic IND/NDA approval.
During his tenure at the Ministry of Food and Drug Safety, Dr. Jeong experienced over 550 IND (Investigational New Drug), 320 NDA (New Drug Application), and 150 bioequivalence (bioequivalence) reviews, and was involved in numerous medical device IND/NDA processes. He also has extensive experience performing inspections for institutions, clients, and CROs.
An official from C&R Research said, “As the demand for new drug development and personalized medicine increases in the global pharmaceutical market, the need for sophisticated clinical trial design and efficient approval procedures is growing,” and added, “Our information headquarters is comprised of four organizations: the BS division, MO (Medical Operation) division, DM (Data Management) division, and RWO (Real World Operation) division. In line with the direction of the company toward becoming a global CRO, each organization establishes work procedures for each business area to meet the requests of overseas regulatory agencies, thereby providing customized integrated services to customers.”
He added, “We expect that the recruitment of Dr. Jeong Ji-won will provide an important foundation for our growth as a global CRO by proactively responding to the rapidly changing market and strengthening our consulting capabilities related to licensing.”
You must be logged in to post a comment.